126 results
10-K
2022 FY
EX-4.4
CTIC
CTI BioPharma Corp
Annual report
6 Mar 23
4:31pm
10-K
2021 FY
EX-4.4
CTIC
CTI BioPharma Corp
Annual report
31 Mar 22
4:31pm
S-8
EX-4.1
CTIC
CTI BioPharma Corp
17 Jun 21
Registration of securities for employees
4:50pm
10-K
2020 FY
EX-4.5
CTIC
CTI BioPharma Corp
Annual report
17 Mar 21
5:22pm
10-K
2019 FY
EX-4.6
CTIC
CTI BioPharma Corp
Annual report
13 Mar 20
12:00am
8-K
EX-4.1
tazh72dk6vt6bfuu
12 Feb 18
Entry into a Material Definitive Agreement
12:00am
8-K
EX-4.2
jj4zexkl5bm6
28 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
EX-4.1
ztsfmvvxi0
28 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
EX-4.1
icn92ttztpx4
26 Sep 17
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
12:00am
8-A12G/A
EX-4.1
9as9b
26 Sep 17
Registration of securities (amended)
12:00am
8-K
EX-4.1
xw6ilmtb3qbsci ux
1 Dec 15
Entry into a Material Definitive Agreement
12:00am
S-8
EX-4.1
1yxbudbmtgs0sn0rk2xm
28 Sep 15
Registration of securities for employees
12:00am
8-K
EX-4.1
7591grq8
10 Jun 15
Entry into a Material Definitive Agreement
12:00am
8-K
EX-4.1
av1py v01
27 Oct 14
CTI Acquires Exclusive Worldwide License to Tosedostat, a Selective Oral Anti-Cancer Therapy
12:00am
S-8
EX-4
bgdxfa7ybg ixib3ahrd
4 Jun 14
Registration of securities for employees
12:00am
8-K
EX-4.1
7bui23q alwtynbr3t
15 Nov 13
Baxter and Cell Therapeutics Announce Worldwide Strategic Collaboration to Develop and Commercialize Pacritinib
12:00am